Abstract
Evidence indicates phenotypic and biological overlap between psychiatric and neurodegenerative disorders. Further identification of underlying mutual and unique biological mechanisms may yield novel multi-disorder and disorder-specific therapeutic targets. The metabolome represents an important domain for target identification as metabolites play critical roles in modulating a diverse range of biological processes. Here, we used Mendelian randomisation (MR) to test the causal effects of ∼1000 plasma metabolites and ∼300 metabolite ratios on anxiety, bipolar disorder, depression, schizophrenia, amyotrophic lateral sclerosis, Alzheimer’s disease, Parkinson’s disease and multiple sclerosis. In total, 85 causal effects involving 77 unique metabolites passed FDR correction and robust sensitivity analyses (IVW-MR OR range: 0.73-1.48; pFDR < 0.05). No evidence of reverse causality was identified. Multivariate analyses implicated sphingolipid metabolism in psychiatric disorder risk and carnitine derivatives in risk for amyotrophic lateral sclerosis and multiple sclerosis. However, polygenic risk scores for prioritised metabolites showed limited prediction in the UK Biobank. Downstream colocalisation in regions containing influential variants identified greater than suggestive evidence (PP.H4 ≥ 0.6) for a shared causal variant for 29 metabolite/psychiatric disorder trait-pairs on chromosome 11 at the FADS gene cluster. Most of these metabolites were lipids containing linoleic or arachidonic acid. Additional colocalisation was identified between the ratio of histidine-to-glutamine, glutamine, Alzheimer’s disease and SPRYD4 gene expression on chromosome 12. Although no single metabolite had a causal effect on a psychiatric and a neurodegenerative disease, results suggest a broad effect of lipids across brain disorders. Metabolites identified here may help inform future targeted interventions.
Competing Interest Statement
CML is on the Scientific Advisory Board of Myriad Neuroscience and has received honoraria for consultancy from UCB. C.L.-Q. has received consultancy fees from Pfizer. C.L.-Q. has received honoraria, travel or speakers' fees from Biogen and research funds from Pfizer and Novo Nordisk. C.L.-Q. is the director of the company BrainLogia. All other authors declare no competing interests.
Funding Statement
LG is funded by the King's College London DRIVE-Health Centre for Doctoral Training and the Perron Institute for Neurological and Translational. JM is supported by the King's Prize Fellowship. This study has been partly delivered through the National Institute for Health and Care Research (NIHR) Maudsley Biomedical Research Centre (BRC). PP is funded by an Alzheimer's Research UK Senior Research Fellowship.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of King's College London gave ethical approval for this work Ethical approval for the UK Biobank study has been granted by the National Information Governance Board for Health and Social Care and the NHS North West Multicentre Research Ethics Committee (11/NW/0382). Data access permission has been granted under UK Biobank application 82877. Written informed consent was obtained from all participants by the UK Biobank.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
